Alector announces phase 1 data on al002 at 12th clinical trials on alzheimer's disease meeting

Alector announces phase 1 data on al002 at the 12th clinical trials on alzheimer’s disease (ctad) meeting.alector inc - al002 was generally safe and well-tolerated in healthy volunteers.alector inc - phase 1b study of al002 in patients with alzheimer's disease ongoing.alector inc - expects to initiate al002 phase 2, proof-of-concept study in 2020.
ALEC Ratings Summary
ALEC Quant Ranking